 The FDA has granted Fast Track Designation to BridgeBio Pharma Incs NASDAQ: BBIO BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i LGMD2i. This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received this year. 